Evidence map›Paper›PMID 38363794›Full record

ArticlePLoS neglected tropical diseases2024

Elimination of lymphatic filariasis as a public health problem in Malawi.

John Chiphwanya, Square Mkwanda, Storn Kabuluzi, Themba Mzilahowa, Bagrey Ngwira, Dorothy E Matipula, Limbikani Chaponda, Paul Ndhlova, Prince Katchika, Chawananga Mahebere Chirambo and 17 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Notes on the threadwormInternational journal for parasitology. Parasites and wildlife · 2025
    Article
  4. Living with Filariasis: Unseen Struggles of a Neglected Disease.The Yale journal of biology and medicine · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Prevalence of elephantiasis, an overlooked disease in Southern Africa: a comprehensive review.The journal of venomous animals and toxins including tropical diseases · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 4 countries.

John ChiphwanyaMinistry of Health, Lilongwe, Malawi.
Square MkwandaMinistry of Health, Lilongwe, Malawi.
Storn KabuluziMinistry of Health, Lilongwe, Malawi.
Themba MzilahowaMalaria Alert Centre, Kamuzu University of Health Sciences, Blantyre, Malawi.
Bagrey NgwiraCentre for Health, Agriculture, Development Research, and Consulting, Blantyre, Malawi.
Dorothy E MatipulaMinistry of Health, Lilongwe, Malawi.
Limbikani ChapondaMinistry of Health, Lilongwe, Malawi.
Paul NdhlovaMinistry of Health, Lilongwe, Malawi.
Prince KatchikaMinistry of Health, Lilongwe, Malawi.
Chawananga Mahebere ChiramboMinistry of Health, Lilongwe, Malawi.
Philemon MosesCentre for Health, Agriculture, Development Research, and Consulting, Blantyre, Malawi.
Justin KumalaMalaria Alert Centre, Kamuzu University of Health Sciences, Blantyre, Malawi.
Martin ChiumiaMalaria Alert Centre, Kamuzu University of Health Sciences, Blantyre, Malawi.
Carrie BarrettCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Hannah BettsCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Joan FahyCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Maria Rebollo PoloCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Lisa ReimerDepartment of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Michelle C StantonCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Brent ThomasCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Sian FreerCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
David H MolyneuxCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Moses J BockarieCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Charles D MackenzieCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Mark J TaylorCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Sarah MartindaleCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Louise A Kelly-HopeCentre for Neglected Tropical Diseases, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.ORCID 0000-0002-3330-7629
Liverpool School of Tropical Medicine · GBMinistry of Health · MWKamuzu Central Hospital · MWBlantyre Institute for Community Ophthalmology · MWUniversity of Liverpool · GB

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundLymphatic filariasis (LF) is a parasitic disease transmitted by mosquitoes, causing severe pain, disfiguring, and disabling clinical conditions such as lymphoedema and hydrocoele. LF is a global public health problem affecting 72 countries, primarily in Africa and Asia. Since 2000, the World Health Organization (WHO) has led the Global Programme to Eliminate Lymphatic Filariasis (GPELF) to support all endemic regions. This paper focuses on the achievements of the Malawi LF Elimination Programme between 2000 and 2020 to eliminate LF as a public health problem, making it the second sub-Saharan country to receive validation from the WHO. METHODOLOGY/PRINCIPAL

findingsThe Malawi LF Programme addressed the widespread prevalence of LF infection and disease across the country, using the recommended WHO GPELF strategies and operational research initiatives in collaboration with key national and international partners. First, to stop the spread of infection (i.e., interrupt transmission) and reduce the circulating filarial antigen prevalence from as high as 74.4% to below the critical threshold of 1-2% prevalence, mass drug administration (MDA) using a two-drug regime was implemented at high coverage rates (>65%) of the total population, with supplementary interventions from other programmes (e.g., malaria vector control). The decline in prevalence was monitored and confirmed over time using several impact assessment and post-treatment surveillance tools including the standard sentinel site, spot check, and transmission assessment surveys and alternative integrated, hotspot, and easy-access group surveys. Second, to alleviate suffering of the affected populations (i.e., control morbidity) the morbidity management and disability prevention (MMDP) package of care was implemented. Specifically, clinical case estimates were obtained via house-to-house patient searching activities; health personnel and patients were trained in self-care protocols for lymphoedema and/or referrals to hospitals for hydrocoele surgery; and the readiness and quality of treatment and services were assessed with new survey tools.

conclusionsMalawi's elimination of LF will ensure that future generations are not infected and suffer from the disfiguring and disabling disease. However, it will be critical that the Malawi LF Elimination programme remains vigilant, focussing on post-elimination surveillance and MMDP implementation and integration into routine health systems to support long-term sustainability and ongoing success. SUMMARY: Lymphatic filariasis, also known as elephantiasis, is a disabling, disfiguring, and painful disease caused by a parasite that infected mosquitoes transmit to millions of people worldwide. Since 2000, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) has supported endemic countries such as Malawi in south-eastern Africa, to eliminate the disease as a public health problem. The Malawi National LF Elimination Programme has worked tirelessly over the past two decades to implement the GPELF recommended strategies to interrupt the transmission with a two-drug regime, and to alleviate suffering in patients with lymphoedema and/or hydrocoele through morbidity management and disability prevention. Additionally, the LF Programme has collaborated with national and international stakeholders to implement a range of supplementary operational research projects to address outstanding knowledge gaps and programmatic barriers. In 2020, the World Health Organisation validated that Malawi had successfully eliminated LF as a public health problem, making it the second country in sub-Saharan Africa to achieve this, which is remarkable given that Malawi previously had very high infection rates. The LF Programme now remains vigilant, putting its efforts towards post-elimination surveillance and the continued implementation of care for patients with chronic conditions. Malawi's elimination of LF will ensure that future generations are not affected by this devastating disease.

Indexed as

AnophelesElephantiasis, FilarialLymphedemaMalariaAnimalsBlindnessHumansMalawiMosquito VectorsPublic Health

Identifiers

PMID38363794
PMCPMC10903958
OpenAlexW4391877777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.